ArticleJournal of global antimicrobial resistance2020
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
Article in Journal of global antimicrobial resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Azithromycin in patients with COVID-19: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2022Pooled it
- A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings.Antibiotics (Basel, Switzerland) · 2025Article
- Is there a correlation between antibiotic use and the severity or post-infection conditions of COVID-19 and other viral infections?Clinical and experimental medicine · 2023Review
- Evaluation of early antibiotic use in patients with non-severe COVID-19 without bacterial infection.International journal of antimicrobial agents · 2022Article
- COVID-19, cytokines, inflammation, and spices: How are they related?Life sciences · 2021Review
- Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review).Experimental and therapeutic medicine · 2021Review
- SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients.Microorganisms · 2021Article
- COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development.Current clinical microbiology reports · 2021Review
- Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2020Article
- The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).International journal of molecular sciences · 2020Review
- Observational
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.